A study in BMC Biotechnology demonstrates that molecular dynamics simulations can guide the mutation of an scFv antibody to ...
The Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not ...
Tech Times on MSN
Stroke survivors, take note: Aggressive blood-pressure target cuts repeat stroke risk by 27% in landmark trial
Stroke prevention blood pressure research reaches a landmark turn: the OPTIMAL-Stroke trial, the largest RCT ever in ischemic ...
Corsair Pharma Announces Positive Outcome from FDA Pre-IND Meeting for TRX-248 Transdermal System for Pulmonary Arterial ...
SYNCHRONIZE-CVOT met its primary endpoint demonstrating the safety of survodutide in terms of major adverse cardiovascular events compared with ...
Apprentices develop expertise after doing monotonous tasks repeatedly and learning from their mistakes. Scientists are no ...
A critical narrative review evaluates the technological advances, manufacturing hurdles, and clinical trial frameworks ...
The glucagon/GLP-1 dual agonist is noninferior to placebo for major adverse cardiovascular events and lowers blood pressure ...
Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on ...
MedPage Today on MSN
M1/M4 agonist relieved schizophrenia symptoms in mid-stage trial
Twice-daily dose hit primary and secondary endpoints ...
Boost ROI with automated rapid-release analytics, digital PCR and sensitive assays; expand contract testing and localize sourcing to reduce tariff costs and delays.Dublin, Nov. 09, 2026 (GLOBE ...
Think they can do neutralization calculations, but get the wrong answer when dealing with sulfuric acid or oxalic acid. Only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results